StonvexLoadingβ¦
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest newsβ¦
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview Β· 3 reports / hour Β· No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro βNext report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals β Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Ξ | Vol |
|---|---|---|---|---|
| 05-13 | $0.83 | $0.83 | +0.30% | 0.1M |
| 05-14 | $0.85 | $0.85 | +0.11% | 0.1M |
| 05-15 | $0.85 | $0.83 | -3.03% | 0.0M |
| 05-18 | $0.84 | $0.77 | -8.30% | 0.2M |
| 05-19 | $0.78 | $0.76 | -2.31% | 0.1M |
Documents are served directly from sec.gov / the issuer's website β Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only β single- indicator triggers in isolation are not a complete trading signal.
No sell-side coverage available for NRSN.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
No SEC filings available for NRSN yet.
We expected SEC EDGAR XBRL data here. The issuer may file under a non-standard form, or the latest filing hasn't been parsed yet β try again later or report it via support.
Public market data, filings, and news are still available on this ticker via the other tabs.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Fundamentals not available for NRSN.
No fundamental metrics available yet for this ticker β common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.